Continuous subcutaneous infusion of ketorolac in cancer neuropathic pain unresponsive to opioid and adjuvant drugs. A case report.
Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.
Ripamonti
C
C
Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy.
Ticozzi
C
C
Zecca
E
E
Rodriguez
C H
CH
De Conno
F
F
D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage*; D005153:Facial Neoplasms / Q000150:complications*; D006394:Hemangiosarcoma / Q000150:complications*; D006801:Humans; D007279:Injections, Subcutaneous; D020910:Ketorolac; D008297:Male; D008875:Middle Aged; D009666:Nose; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D014046:Tolmetin / Q000008:administration & dosage / Q000031:analogs & derivatives*
D018712:Analgesics, Non-Narcotic; D014046:Tolmetin; D020910:Ketorolac